WAGR Syndrome (11p13 deletion)
Log in to starLast updated Nov 3, 2026
Log in to add personal notes on this page.
A newborn is noted to have aniridia. Given this finding, the provider orders a CMA which shows an 11p13 deletion. The care team initiates Wilms tumor surveillance.
- AD, typically de novo; contiguous gene deletion at 11p13
- Always includes WT1 (Wilms tumor protein, a transcription factor and tumor suppressor) and PAX6 (aniridia); haploinsufficiency of each
Each letter of WAGR traces to haploinsufficiency of a gene inside the deletion:
- WT1 encodes a transcription factor that directs cell differentiation in the kidney, urinary tract, and gonadal progenitor cells, and it also acts as a tumor suppressor. Half the normal dose explains the Wilms tumor risk (about 50% overall, mostly before age 5) and the genital anomalies, which resemble those of WT1 disorder.
- PAX6 encodes a paired box DNA-binding protein that controls organogenesis; its loss gives the aniridia and the other features of PAX6 aniridia syndrome.
- BDNF, when the deletion includes it, is associated with hyperphagia and childhood-onset obesity; obesity is less common when BDNF is spared.
- ALX4 and EXT2, when a larger deletion reaches them, add Potocki-Shaffer syndrome: enlarged parietal foramina and multiple osteochondromas.
The genes behind the neurodevelopmental range are not established. ELP4, PRRG4, and SLC1A2 are candidates, but small numbers prevent firm conclusions. Low-level mosaicism for the deletion has been reported and can be missed by a standard microarray, so a strong clinical suspicion warrants a test that accounts for it.
WAGR
- Wilms tumor risk (~50%; highest risk under age 8)
- Aniridia (absence of iris)
- Genitourinary anomalies (cryptorchidism, hypospadias)
- Range of developmental delays (as with most microdeletion syndromes)
- Chromosomal microarray (CMA) is the test of choice when WAGR is suspected, because the cause is a deletion that an exome without copy-number calling can miss; it defines the extent of the 11p13 deletion, including involvement of WT1 and PAX6
- Isolated aniridia warrants PAX6 and 11p13 evaluation; finding a contiguous WT1 deletion establishes WAGR and triggers Wilms tumor surveillance
- WT1 involvement also raises the risk of nephropathy, so confirm whether WT1 is within the deleted segment
- Wilms tumor surveillance: renal ultrasound every 3 months until age 8
- Ophthalmologic evaluation